ScreenerHero
SOBISwedish Orphan Biovitrum AB (publ)
STO · SE · Healthcare · Drug Manufacturers - Specialty & Generic · sobi.com
460.00SEK-0.30%Mkt Cap: 15.34B $P/E: 117.35

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap15.34B $
Enterprise Value16.91B $
Revenue (TTM)2.93B $
Gross Profit2.10B $
Net Income (TTM)45.72M $
Revenue/Share8.478 USD
Last Price460.00 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.1K
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0000872095
Valuation
P/E (Trailing)117.35
P/E (Forward)29.52
PEG0.32
EV/EBITDA14.24
EV/Revenue5.77
P/S5.23
P/B3.77
EPS (TTM)3.92
EPS (Forward)15.55
52W Range
262.8088% of range487.00
52W High487.00 SEK
52W Low262.80 SEK
Profitability
Gross Margin77.86%
Oper. Margin25.26%
EBITDA Margin40.54%
Profit Margin1.69%
ROE1.27%
ROA0.71%
Growth
Revenue Growth27.00%
Earnings Growth71.60%
Cash Flow & Leverage
Operating CF819.26M $
CapEx (TTM)301.59M $
FCF Margin11.15%
FCF Yield2.13%
Net Debt1.58B $
Net Debt/EBITDA1.33
Balance Sheet
Debt/Equity0.30
Current Ratio0.88
Quick Ratio0.55
Book Value/Sh121.69 SEK
Cash/Share3.116 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)497.58 SEK
Upside (mean)+8.2%
Target Range350.00 SEK – 575.00 SEK
SEK350.00+8.2% to meanSEK575.00
# Analysts12
Ownership
Shares Out.347.29M
Float223.20M
Insiders10.05%
Institutions75.15%
Technical
SMA 50457.90 (+0.5%)
SMA 200399.01 (+15.3%)
Beta0.28
S&P 52W Chg18.16%
Avg Vol (30d)385.42K
Avg Vol (10d)329.04K
Technical Indicators
RSI (14)53.7
MACD-0.2832
MACD Signal-1.9317
MACD Hist.+1.6485
BB Upper479.97 SEK
BB Middle454.87 SEK
BB Lower429.77 SEK
BB Width11.03%
ATR (14)12.47 SEK
Vol Ratio (20d)0.52x